Home SPRO
2.021
  Price2.37%   -0.049
 
loading
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Aquilo Capital Management, LLC 10% Owner Apr 26 Buy 5.24 39,727 207,971 5,321,231
Aquilo Capital Management, LLC 10% Owner Mar 30 Buy 8.79 50,000 439,420 5,281,504
Aquilo Capital Management, LLC 10% Owner Mar 14 Buy 7.63 23,708 180,797 5,231,504
Aquilo Capital Management, LLC 10% Owner Feb 28 Buy 9.53 44,833 427,227 5,207,796
Aquilo Capital Management, LLC 10% Owner Feb 18 Buy 9.24 14,828 137,039 5,162,963
Aquilo Capital Management, LLC 10% Owner Jan 31 Buy 11.59 125,000 1,448,262 5,148,135
Aquilo Capital Management, LLC 10% Owner Jan 24 Buy 10.89 1,599 17,418 5,023,135
Aquilo Capital Management, LLC 10% Owner Jan 18 Buy 12.41 48,488 601,964 5,021,536
Aquilo Capital Management, LLC 10% Owner Jan 10 Buy 12.93 8,867 114,609 4,973,048
Aquilo Capital Management, LLC 10% Owner Dec 31 Buy 15.75 125,000 1,969,025 4,964,181
Aquilo Capital Management, LLC 10% Owner Dec 30 Buy 15.77 50,000 788,610 4,839,181
Aquilo Capital Management, LLC 10% Owner Dec 29 Buy 14.64 75,493 1,105,263 4,789,181
Mahadevia Ankit CEO and President Dec 27 Option Exercise 5.90 8,000 47,200 152,036
Mahadevia Ankit CEO and President Dec 27 Sale 14.58 8,000 116,666 144,036
Aquilo Capital Management, LLC 10% Owner Oct 29 Buy 17.53 150,000 2,630,175 4,713,688
Aquilo Capital Management, LLC 10% Owner Sep 30 Buy 18.65 134,543 2,509,173 4,563,688
Aquilo Capital Management, LLC 10% Owner Sep 14 Buy 18.49 2,156 39,872 4,429,145
Aquilo Capital Management, LLC 10% Owner Sep 13 Buy 18.56 44,210 820,675 4,426,989
Aquilo Capital Management, LLC 10% Owner Sep 09 Buy 18.50 24,749 457,792 4,382,779
Aquilo Capital Management, LLC 10% Owner Aug 31 Buy 18.93 48,645 920,660 4,358,030
Aquilo Capital Management, LLC 10% Owner Aug 30 Buy 17.87 44,042 786,859 4,309,385
Aquilo Capital Management, LLC 10% Owner Aug 27 Buy 16.88 13,957 235,531 4,265,343
Aquilo Capital Management, LLC 10% Owner Aug 26 Buy 16.55 22,982 380,322 4,251,386
Aquilo Capital Management, LLC 10% Owner Aug 24 Buy 16.28 40,170 653,795 4,228,404
Aquilo Capital Management, LLC 10% Owner Aug 23 Buy 16.33 137,835 2,251,342 4,188,234
Aquilo Capital Management, LLC 10% Owner Aug 20 Buy 14.86 221,190 3,286,906 4,050,399
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Cap:    |  Volume (24h):